Suven Life Sciences to present pre-clinical data of 5-HT 6 antagonists

Suven Life Sciences Ltd has announced that the Company will be presenting the Pre-clinical data of their promising lead compounds, 5-HT 6 antagonists, highly selective small molecule drug candidates, being developed for the treatment of Mild Cognitive impairment (MCI) associated with Alzheimer’s disease or Schizophrenia, Parkinson and Obesity diseases with significant unmet medical need and for which current treatment options are insufficient.

"We are encouraged by the results of these preclinical studies which lead us to believe that these selected 5HT6 antagonists may provide a novel, safe and effective approach of treating diseases like MCI, Alzheimer’s, Schizophrenia, Parkinson’s and obesity" says Venkat Jasti, CEO of the Company. The Company has a number of programs in each of these areas, focusing on novel approaches that may hold promise for the development of new therapies for patients.

Neuroscience is the annual meeting of the Society for Neuroscience (SFN). More than 30,000 scientists from all over the world will attend this year meeting. Neuroscience 2006, the Society’s 36th annual meeting, to be held at the Georgia World Congress Center, in Atlanta, GA., from October 14-18, 2006. Every year the Society for Neuroscience provides the premier venue for neuroscientists around the world to share their research findings.

Source : Equity Bulls

Keywords